Company adds experienced clinical development expert to its board of directors Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary
Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, announced today the appointment of Dr. Adrian Senderowicz to its Board of Directors. Dr. Senderowicz is a board-certified
Bio Farma akan melakukan implementasi transformasi digital serta percepatan peluncuran produk di pasar time to market dengan menggunakan Produk Google Cloud.
Evotec AG: Evotec SE Reports Results for The First Quarter 2021 and Provides Corporate Update
GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO
CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC
HAMBURG, GERMANY / ACCESSWIRE / May 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and corporate updates for the first quarter 2021.
HIGHLIGHTS
RECORD LIKE-FOR-LIKE GROWTH OF BASE BUSINESS, STRONG BALANCE SHEET SUPPORTS ACCELERATING GROWTH
Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects
Evotec SE reports results for the first quarter 2021 and provides corporate update
SUCCESSFUL START TO 2021 WITH STRONG STRATEGIC POSITION AND LONG-TERM STRATEGY: ACTION PLAN 2025 THE DATA-DRIVEN R&D AUTOBAHN TO CURES
GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO
CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC
Hamburg, Germany, 11 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and corporate updates for the first quarter 2021. HIGHLIGHTS RECORD LIKE-FOR-LIKE GROWTH OF BASE BUSINESS, STRONG BALANCE SHEET SUPPORTS ACCELERATING GROWTH Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects